Date: 2012-08-08
Type of information:
phase: 2b
Announcement: results
Company: BTG (UK) AstraZeneca (UK)
Product: AZD9773 (CytoFab™)
Action mechanism:
Disease: sepsis
septic shock
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: BTG has announces top-line data from a global double-blind Phase IIb study comparing the efficacy and safety of two doses of AZD9773 (CytoFab™) with placebo in patients with severe sepsis and/or septic shock, conducted by AstraZeneca.
Treatment with AZD9773 did not show any significant improvements versus placebo in respect of the primary endpoint, ventilator-free days, or secondary endpoints including mortality. In light of these data, AstraZeneca has decided to halt any further development of AZD9773 for the treatment of severe sepsis and/or septic shock, and will hand the asset back to BTG.
BTG does not anticipate conducting any further development of AZD9773. Consequently, BTG anticipates taking a charge of approximately £28m in the current financial year, of which £25m relates to a non-cash impairment of intangible and tangible fixed assets.
